The Impact of Metformin on Mortality in Patients with Type 2 Diabetes Mellitus: a Prospective Cohort Study

Overview

Journal Endocrine

Specialty Endocrinology

Date 2024 Aug 27

PMID 39190051

Authors

Bocheng Zhang

Ying Cao

Zhenan Qu

Yulan Sun

Xiaoyuan Tian

Affiliations

Soon will be listed here.

Abstract

Background: Metformin, a widely used antihyperglycemic drug, has shown efficacy in treating type 2 diabetes mellitus (T2DM) and is associated with potential benefits beyond glycemic control. This study investigates the impact of metformin on mortality in T2DM patients using a prospective cohort design utilizing data from the National Health and Nutrition Examination Survey (NHANES).

Methods: In NHANES 1999-2014, a total of 5813 representative participants aged 20 and above with T2DM were included in the analysis. We utilized Kaplan-Meier survival curves and multivariate Cox regression analysis to investigate the impact of metformin on both all-cause mortality and cause-specific mortality among patients with T2DM.

Results: Kaplan-Meier analysis showed a significant reduction in all-cause and cause-specific mortality in metformin users compared to non-users (p < 0.05). Multivariate Cox regression confirmed these findings, indicating that metformin use was associated with a 18% reduction in all-cause mortality (HR = 0.82, 95% CI = 0.73-0.92, p < 0.001) and 25% reduction in cardiovascular mortality (HR = 0.75, 95% CI = 0.60-0.94, p = 0.01).

Conclusion: Our results suggest that metformin significantly reduces all-cause and cardiovascular mortality in T2DM patients, highlighting its potential benefits beyond glycemic control. These results contribute to the existing literature by providing robust evidence from a large prospective cohort study. However, further research is needed to validate these findings and elucidate the underlying mechanisms controlling the effects of metformin on mortality outcomes in individuals with T2DM.

References

Bailey C . Metformin: historical overview. Diabetologia. 2017; 60(9):1566-1576. DOI: 10.1007/s00125-017-4318-z. View

Tobar N, Rocha G, Santos A, Guadagnini D, Assalin H, Camargo J . Metformin acts in the gut and induces gut-liver crosstalk. Proc Natl Acad Sci U S A. 2023; 120(4):e2211933120. PMC: 9942892. DOI: 10.1073/pnas.2211933120. View

Karlsson F, Tremaroli V, Nookaew I, Bergstrom G, Behre C, Fagerberg B . Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013; 498(7452):99-103. DOI: 10.1038/nature12198. View

de Maranon A, Diaz-Pozo P, Canet F, Diaz-Morales N, Abad-Jimenez Z, Lopez-Domenech S . Metformin modulates mitochondrial function and mitophagy in peripheral blood mononuclear cells from type 2 diabetic patients. Redox Biol. 2022; 53:102342. PMC: 9124713. DOI: 10.1016/j.redox.2022.102342. View

Stratton I, Adler A, Neil H, Matthews D, Manley S, Cull C . Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321(7258):405-12. PMC: 27454. DOI: 10.1136/bmj.321.7258.405. View

Johnson J, Simpson S, Toth E, Majumdar S . Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with Type 2 diabetes. Diabet Med. 2005; 22(4):497-502. DOI: 10.1111/j.1464-5491.2005.01448.x. View

Holman R, Paul S, Bethel M, Matthews D, Neil H . 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15):1577-89. DOI: 10.1056/NEJMoa0806470. View

Lee M, Hsu C, Wahlqvist M, Tsai H, Chang Y, Huang Y . Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer. 2011; 11:20. PMC: 3031263. DOI: 10.1186/1471-2407-11-20. View

Kang J, Jeong S, Shin D, Cho M, Cho J, Kim J . The Associations of Aspirin, Statins, and Metformin With Lung Cancer Risk and Related Mortality: A Time-Dependent Analysis of Population-Based Nationally Representative Data. J Thorac Oncol. 2020; 16(1):76-88. DOI: 10.1016/j.jtho.2020.08.021. View

10.

Barzilai N, Crandall J, Kritchevsky S, Espeland M . Metformin as a Tool to Target Aging. Cell Metab. 2016; 23(6):1060-1065. PMC: 5943638. DOI: 10.1016/j.cmet.2016.05.011. View

11.

Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel J . Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med. 2012; 9(4):e1001204. PMC: 3323508. DOI: 10.1371/journal.pmed.1001204. View

12.

Griffin S, Leaver J, Irving G . Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017; 60(9):1620-1629. PMC: 5552849. DOI: 10.1007/s00125-017-4337-9. View

13.

Kautzky-Willer A, Leutner M, Harreiter J . Sex differences in type 2 diabetes. Diabetologia. 2023; 66(6):986-1002. PMC: 10163139. DOI: 10.1007/s00125-023-05891-x. View

14.

Ding Y, Zhou Y, Ling P, Feng X, Luo S, Zheng X . Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function. Theranostics. 2021; 11(19):9376-9396. PMC: 8490502. DOI: 10.7150/thno.64706. View

15.

Zheng J, Xu M, Yang Q, Hu C, Walker V, Lu J . Efficacy of metformin targets on cardiometabolic health in the general population and non-diabetic individuals: a Mendelian randomization study. EBioMedicine. 2023; 96:104803. PMC: 10514430. DOI: 10.1016/j.ebiom.2023.104803. View

16.

Wen J, Yi Z, Chen Y, Huang J, Mao X, Zhang L . Efficacy of metformin therapy in patients with cancer: a meta-analysis of 22 randomised controlled trials. BMC Med. 2022; 20(1):402. PMC: 9594974. DOI: 10.1186/s12916-022-02599-4. View

17.

Lusica P, Eugenio K, Sacdalan D, Jimeno C . A systematic review and meta-analysis on the efficacy and safety of metformin as adjunctive therapy among women with metastatic breast cancer. Cancer Treat Res Commun. 2021; 29:100457. DOI: 10.1016/j.ctarc.2021.100457. View

18.

Kulkarni A, Gubbi S, Barzilai N . Benefits of Metformin in Attenuating the Hallmarks of Aging. Cell Metab. 2020; 32(1):15-30. PMC: 7347426. DOI: 10.1016/j.cmet.2020.04.001. View

19.

Foretz M, Guigas B, Viollet B . Metformin: update on mechanisms of action and repurposing potential. Nat Rev Endocrinol. 2023; 19(8):460-476. PMC: 10153049. DOI: 10.1038/s41574-023-00833-4. View

20.

Salpeter S, Greyber E, Pasternak G, Salpeter E . Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010; (4):CD002967. PMC: 7138050. DOI: 10.1002/14651858.CD002967.pub4. View